

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $1.62
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 6, 26 | Maxim Group | downgrade | Buy | Hold |
| Aug 14, 24 | Roth MKM | maintain | Buy | Buy |
| Jun 12, 24 | Roth MKM | maintain | Buy | Buy |
| Aug 14, 23 | Roth MKM | maintain | Buy | Buy |
| Dec 7, 22 | Roth Capital | maintain | Buy | Buy |
| Sep 28, 22 | Maxim Group | maintain | Buy | Buy |
| Dec 1, 21 | Roth Capital | maintain | Buy |
| Buy |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 30.15 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 25.48 | Oscillator | Neutral |
| Williams %R (14) | -66.67 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.38 (Hist 0.04) | Oscillator | Buy |
| Average Directional Index (14) | 51.44 (+DI 9.7 / -DI 32.1) | Trend | Strong Sell |
| EMA 20 | 1.89 | MA | Strong Sell |
| SMA 20 | 1.88 | MA | Strong Sell |
| EMA 50 | 2.78 | MA | Strong Sell |
| SMA 50 | 2.80 | MA | Strong Sell |
| SMA 200 | 6.85 | MA | Strong Sell |
FY2025 · 10-K disclosure
Stock news · updated daily
Biorestorative Therapies, Inc. (NASDAQ: BRTX - Get Free Report) was the target of a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 11,586 shares, a decrease of 69.2% from the August 31st total of 37,641 shares. Currently, 1.0% of the company's stock are short sold.
MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company's Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company's common stock (the “Common Stock”). The Company was not required to obtain stockholder approval to effectuate the Reverse Stock Split under Nevada law. The Company filed a certificate of change with the Secretary of State of the State of Nevada, which is expected to become effective as of 4:30 P.M. Eastern Time on September 7, 2026. The Common Stock will begin trading on The Nasdaq Capital Market on a reverse split-adjusted basis at the start of trading on September 8, 2026, under the symbol “BRTX” and under a new CUSIP number, 090655705. The Company is effecting the Reverse Stock Split with the intention of regaining compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| May 13, 2026 | -6.00 | -0.24 | Beat 96.0% | $23.17K |
| Mar 26, 2026 | -7.40 | -7.40 | Beat 0.0% | $20.00K |
| Nov 12, 2025 | -7.20 | -6.60 | Beat 8.3% | $11.80K |
| Aug 12, 2025 | -7.40 | -0.30 | Beat 95.9% | $303.0K |
| May 14, 2025 | -6.40 | -12.80 | Miss -100.0% | $25.00K |
| Apr 4, 2025 | -5.40 | -7.50 | Miss -38.9% | $500.0K |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jul 13, 26 | Randhawa Esha | director: | 0 | — | |
| Jun 10, 26 | Grasso Mika | director: | 0 | — | |
| Jun 10, 26 | Dhaliwal Jatinder | director: | 0 | — | |
| Jun 10, 26 | Field Katharyn | director: | 0 | — | |
| Oct 6, 25 | Silva Francisco | director, officer: VP of Research and Development | A-Award | 11,719 @ $1.60 | $18.75K |
| Oct 6, 25 | Silva Francisco | director, officer: VP of Research and Development | A-Award | 11,719 @ $2.75 | $32.23K |
| Oct 6, 25 | Alstodt Lance | director, 10 percent owner, officer: President, CEO, COB | A-Award | 15,625 @ $1.60 | $25.00K |
| Oct 6, 25 | Alstodt Lance | director, 10 percent owner, officer: President, CEO, COB | A-Award | 11,719 @ $2.75 | $32.23K |
TTM vs. 5-year historical average (annual ratios)
| Metric | BRTX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.1x | -0.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.2x | EPS est. -6.60 | Elevated |
| Price / Book | 0.5x | 6.6x | Discount |
| Price / Sales | 6.3x | 60.5x | Discount |
| EV / EBITDA | 0.1x | -0.5x | Discount |
| Return on equity | -423.8% | — | Weak |
| Gross margin | 92.1% | 97.3% | In line |
| Debt / Equity | 0.01 | 0.02 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -58.32 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 9, 2026 | 2026-10-09 16:05:40 | View |
| 8-K | Sep 11, 2026 | 2026-09-11 09:29:03 | View |
| 8-K/A | Sep 10, 2026 | 2026-09-10 16:30:24 | View |
| 8-K | Sep 2, 2026 | 2026-09-02 17:29:10 | View |
| 8-K | Sep 2, 2026 | 2026-09-01 18:09:03 | View |
| 8-K | Aug 25, 2026 | 2026-08-25 17:00:56 | View |
| NT 10-Q | Aug 14, 2026 | 2026-08-14 16:25:10 | View |
| 8-K | Aug 14, 2026 | 2026-08-14 16:15:56 | View |
| SC 13G/A | Aug 3, 2026 | 2026-08-03 16:17:56 | View |
| 3 | Jul 30, 2026 | 2026-07-30 18:54:24 | View |
Proxy statement (DEF 14A) disclosures